What the Shop Lists, and Why a Listing Is Not a Batch Audit
The shop’s current homepage wording lists “CoAs Janoshik Analytical Reports”, and the product pages and FAQs describe a CoA for every product covering HPLC purity and identity, with independent testing and final UK verification before release. The About page describes a fuller testing framework: purity, identity, heavy metals and endotoxin evaluation of submitted samples. For a contract research team, that is useful orientation, but it is not an audit trail. A shop-level statement tells the researcher what documentation the supplier says it publishes; the batch-level document tells the team what was actually tested for the material in hand. The two should never be conflated.
Where the shop publishes headline purity wording such as ≥99% or 99.1%, treat it as current published wording to be reconfirmed against the specific batch CoA. The FAQs state that exact purity is stated on the CoA, and that is the document a materials manager should open rather than relying on a category badge or product summary. The same discipline applies to identity and contaminant screening: if the report lists HPLC, heavy-metal or endotoxin work, check that the report in front of you corresponds to the product and sample reference you are holding, not merely to a product name that appears elsewhere in the catalogue. Materials supplied by Research Sciences are research-use-only and are not for human or veterinary use.
Brand history also needs care. The FAQs describe Research Sciences as the parent company of Imperial Peptides UK, with Imperial Peptides UK continuing as a brand; some older pages and blog posts still use Imperial Sciences UK or Imperial Peptides UK wording. When a contract team checks documentation, the controlling details are the product identity, the batch or Internal Test Reference (ITR), and the vial label reference, not the brand name in a historical page header. A Janoshik report listed by the shop should be opened as the CoA supplied for that specific batch, and any discrepancy should be raised with the shop using the vial reference. A contract research team should also keep its own record of which document version was reviewed, because procurement and scientific review often happen in different departments.
A Batch-Level Verification Workflow for the Contract Team
Begin with the current research catalogue rather than a cached screenshot. A practical starting point is to review the current listings at Buy peptides uk, then open the individual product page and its batch CoA for the item being considered. The vial label reference combines the SKU code and expiry date, for example BPC10-03/27, and links to the corresponding CoA. The materials manager should capture that reference, quote it in any documentation query, and attach the CoA copy to the internal batch record. This simple step prevents a contract team from comparing a report for one delivery against vials from another.
When the CoA is open, check it as a document rather than as a marketing asset. Confirm the product name, the report issuer where stated, the sample identifier, the ITR where present, and the analytical method described. If the report is a Janoshik Analytical report, verify that the sample identifier and product details align with the shop’s listing and the vial reference. Where the report provides a report number, issue date, method heading or signature field, record those details in the audit file; where it does not, do not invent them. The contract team should also separate what the shop states about testing from what the report itself demonstrates. The shop describes HPLC testing for purity and identity, and the About page describes heavy metals and endotoxin screening; if the specific CoA does not show the data the study requires, raise a documentation query rather than assuming the missing information exists.
Treat the ITR as a link, not a lot certificate
The FAQs contain an important limitation for contract research teams: restocked products may carry the same ITR as earlier stock. The ITR links to associated sample testing reports, but it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. This matters when a contract team needs lot-level traceability. Record the ITR exactly as shown, note the limitation in the procurement file, and seek written clarification from the shop where the study design requires stronger batch continuity. Do not upgrade an ITR into a lot certificate by assumption.
Do not infer identity from packaging
Vial cap colours and other packaging may vary. The shop states that cap colour is not an indicator of identity, analytical quality or manufacturing origin, so a contract team should never use it as a short-cut when matching vials to reports. The same principle applies to blended materials: the FAQs state that the shop does not supply blended peptides and recommends buying peptides individually and combining only within a controlled experimental design. For a contract team, that means the documentation trail should follow individual RUO vials and their CoAs, not a blend that the shop does not list. All materials remain research-use-only and not for human or veterinary use.
Red Flags, Records and Shared Responsibilities
Several red flags should stop a contract research team before the material enters the laboratory workflow. A CoA supplied as an image with no product name or sample reference, a report that matches a similar product but not the exact SKU and expiry reference, an ITR presented as proof of a single production lot, or a cap colour used to justify identity are all reasons to pause and query the shop. A Janoshik report should be checked against the vial reference and the shop’s product page, not accepted because it carries a recognisable logo. If a screenshot has been forwarded internally, obtain the shop-supplied CoA from the product page or ask the shop to clarify the batch link in writing. Documentation queries should be specific: product name, vial reference, ITR if shown, and the point that needs clarification.
Record-keeping should be proportionate but complete. The procurement file should hold the product page reference, the CoA copy, the vial label reference and any correspondence about batch identity. The scientific lead should confirm that the analytical information is suitable for the intended in-vitro study, while the materials manager confirms that the supplier documentation matches the delivered vial. Where reconstitution is part of the in-vitro workflow, record the diluent volume and resulting concentration for the assay, and keep the shop calculator’s research-use-only limitation with the record; it must not be used for human or veterinary dosing. The shop’s quick guide states that lyophilised peptides should be stored at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with reconstituted material kept at 2–8°C for short-term laboratory use. Those storage conditions belong in the team’s own records as well as in the supplier’s guidance.
Responsibility should be shared but explicit. The purchaser remains responsible for lawful use, safe handling, storage and disposal, and for compliance with relevant UK regulations including COSHH and laboratory safety standards. The shop labels products “For Research Use Only – Not for Human Consumption” and describes this as its stated position in line with MHRA guidance; that is supplier wording, not legal advice, and the contract team should apply its own compliance review before the material enters the laboratory. Any Janoshik report or CoA should be filed with the batch record, and any unresolved discrepancy should remain open until the shop confirms the documentation link in writing. Materials are research-use-only and not for human or veterinary use.